Mark Avagliano
2019
In 2019, Mark Avagliano earned a total compensation of $5.5M as Chief Business Officer at G1 Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $142,800 |
|---|---|
| Option Awards | $5,100,560 |
| Salary | $181,913 |
| Other | $53,117 |
| Total | $5,478,390 |
Avagliano received $5.1M in option awards, accounting for 93% of the total pay in 2019.
Avagliano also received $142.8K in non-equity incentive plan, $181.9K in salary and $53.1K in other compensation.
Rankings
In 2019, Mark Avagliano's compensation ranked 1,943rd out of 13,971 executives tracked by ExecPay. In other words, Avagliano earned more than 86.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,943 out of 13,971 | 86th |
Division Manufacturing | 704 out of 5,698 | 88th |
Major group Chemicals And Allied Products | 215 out of 2,197 | 90th |
Industry group Drugs | 172 out of 1,883 | 91st |
Industry Pharmaceutical Preparations | 128 out of 1,395 | 91st |
Pay ratio
| Mark Avagliano's Pay | $5,478,390 |
|---|---|
| Median Employee's Pay | $213,060 |
| Pay Ratio | 26to 1 |
In 2019, the annual total compensation of Mark Avagliano was $5,478,390.
The annual total compensation of the median employee at G1 Therapeutics was $213,060.
The ratio of Mark Avagliano's pay to the pay of median employee was therefore 26 to one.
Source: SEC filing on April 24, 2020.
Avagliano's colleagues
We found five more compensation records of executives who worked with Mark Avagliano at G1 Therapeutics in 2019.